How to Help Your Patients Find Leuprolide in Stock: A Provider's Guide

Your Patient Needs Leuprolide — And It's Out of Stock

You've written the prescription. The prior authorization went through. Your patient is scheduled for their injection. And then you get the call: your distributor can't fill the order, or the patient's pharmacy doesn't have it.

This scenario has become all too common since 2020, when the Leuprolide (Lupron Depot) shortage first appeared on the ASHP drug shortage list. Six years later, intermittent supply disruptions continue to affect practices across urology, oncology, gynecology, and pediatric endocrinology.

This guide provides actionable steps your practice can take to minimize the impact on patient care.

Current Availability Snapshot

As of early 2026, here's where Leuprolide supply stands:

• Lupron Depot (AbbVie, IM): Intermittent availability across most strengths. The 3.75mg, 11.25mg, 22.5mg, and pediatric formulations are most frequently affected.
• Eligard (Tolmar, SC): Generally available. Labeled for prostate cancer only. Strengths: 7.5mg (1-month), 22.5mg (3-month), 30mg (4-month), 45mg (6-month).
• Camcevi (Tolmar, SC): Available. 42mg, 6-month formulation for prostate cancer.
• Fensolvi (Tolmar, SC): Available. 45mg, 6-month formulation for central precocious puberty.
• Generic leuprolide 5mg/mL (SC daily): Available but generally impractical for most patient populations.

Why Patients Can't Find It

Understanding the supply dynamics can help you communicate with frustrated patients and make better sourcing decisions:

• Single-source brand: Lupron Depot has no FDA-approved generic equivalent for the depot formulation. AbbVie is the sole manufacturer.
• Complex manufacturing: The microsphere depot technology is difficult to produce and scale, leading to capacity constraints.
• Retail pharmacy limitations: Chain pharmacies rely on shared wholesale distributors. When allocation is restricted, all locations in a chain may be affected simultaneously.
• Rising demand: Expanded use of GnRH agonists across multiple therapeutic areas continues to outpace constrained supply.

What Providers Can Do: 5 Practical Steps

Step 1: Diversify Your Distribution Sources

Don't rely on a single distributor. Establish accounts with multiple specialty distributors to increase your chances of securing inventory:

• McKesson Specialty
• AmerisourceBergen / Cencora
• Cardinal Health Specialty

Each distributor may receive different allocations at different times. Having multiple accounts gives you more chances to locate available stock.

Step 2: Order Proactively, Not Reactively

Don't wait until the patient is in the chair to order. Build a 2-4 week lead time into your ordering process. If you know a patient's next injection date, place the order as early as your distributor allows. During allocation periods, ordering early in the cycle (Monday/Tuesday) tends to be more successful.

Step 3: Leverage the Medfinder Provider Platform

Medfinder for Providers tracks real-time pharmacy availability for Leuprolide and related medications. If your practice can't source the drug directly, you can use Medfinder to identify nearby pharmacies or specialty pharmacies that have it in stock, and coordinate with the patient accordingly.

Step 4: Maintain a Current Alternative Protocol

Having a pre-established protocol for when Lupron Depot is unavailable can save critical time. Here's a framework by indication:

Advanced Prostate Cancer:

• First alternative: Eligard (same drug, SC route, same manufacturer as Camcevi)
• Second alternative: Goserelin (Zoladex) — GnRH agonist, SC implant, AstraZeneca
• Third alternative: Triptorelin (Trelstar) — GnRH agonist, IM, Verity Pharmaceuticals
• Oral option: Relugolix (Orgovyx) — oral GnRH antagonist, no injection needed
• If flare is a concern: Degarelix (Firmagon) — GnRH antagonist, no testosterone flare

Endometriosis:

• First alternative: Goserelin (Zoladex 3.6mg monthly) — FDA-approved for endometriosis
• Oral option: Elagolix (Orilissa) — oral GnRH antagonist, FDA-approved for endometriosis
• Note: Eligard is NOT appropriate (not approved for endometriosis, dosing doesn't match)

Uterine Fibroids:

• First alternative: Goserelin (Zoladex) — approved for related indications
• Oral option: Elagolix with add-back therapy (Oriahnn) — FDA-approved for fibroids

Central Precocious Puberty:

• First alternative: Fensolvi (45mg SC every 6 months)
• Second alternative: Triptorelin (Triptodur) — IM every 6 months
• Implant option: Histrelin (Supprelin LA) — SC implant, 12-month duration

Step 5: Pre-Authorize Alternatives Before You Need Them

For patients who are stable on Leuprolide but at risk of supply disruption, consider proactively obtaining prior authorization for a backup medication. Document the shortage as the clinical rationale. This way, if Lupron Depot becomes unavailable, you can switch without treatment delay.

Alternative Therapies: Quick Reference

For a comprehensive review of all Leuprolide alternatives with clinical details, see our alternatives guide. For the provider-specific shortage analysis, see our prescriber shortage briefing.

Workflow Tips for Your Practice

• Designate a shortage coordinator. Have one staff member responsible for monitoring drug availability and communicating with distributors. This prevents duplication of effort and ensures nothing falls through the cracks.
• Track patient injection schedules centrally. Use your EHR or a shared spreadsheet to know exactly when each patient's next dose is due, so you can start sourcing early.
• Communicate proactively with patients. Don't wait for the patient to discover the shortage at their appointment. If you know stock is uncertain, reach out in advance so they have time to explore options.
• Document everything. Record the shortage in your clinical notes, including efforts to source the medication and the clinical rationale for any switches. This supports continuity of care and facilitates insurance appeals.
• Direct patients to resources. Share medfinder.com with patients so they can independently check pharmacy availability. For savings help, point them to our patient savings guide.

Final Thoughts

The Leuprolide shortage is a systemic challenge that requires systemic solutions — but in the meantime, individual practices can make a meaningful difference by planning ahead, diversifying sources, and maintaining flexibility in their prescribing approach.

Visit medfinder.com/providers for provider-specific tools and resources to support your patients through this shortage and beyond.